• FDA Approves First Cancer Drug through New Oncology Review Pilot americanpharmaceuticalreview
    July 24, 2018
    The U.S. Food and Drug Administration (FDA) approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive,
PharmaSources Customer Service